jayempi
nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
alzane 5 mg/ml injekční roztok
laboratorios syva, s.a.u. - atipamezolu - injekční roztok - 5mg/ml - antidota - psi, kočky
ceftiomax 50 mg/ml injekční suspenze
laboratorios calier s.a. - ceftiofur - injekční suspenze - 50mg/ml - cefalosporiny třetí generace - prasata, skot
colisuin-tp injekční emulze
laboratorios hipra s.a. - escherichia vakcíny - injekční emulze - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - prasata
cunipravac - rhd injekční emulze
laboratorios hipra s.a. - rabbit haemorrhagic disease virus vakcíny - injekční emulze - inaktivované virové vakcíny - králíci, od stáří 2 měsíců
dinalgen 60 mg/ml
laboratorios dr. esteve, s.a. - ketoprofen - injekční roztok - 60mg/ml - deriváty kyseliny propionové - prasata
dorbene 1 mg/ml injekční roztok
laboratorios syva, s.a.u. - medetomidin - injekční roztok - 1mg/ml - jiná hypnotika a sedativa - kočky, psi
doxycycline calier 500.0 mg/g prášek pro podání v pitné vodě
laboratorios calier s.a. - doxycyklin - prášek pro podání v pitné vodě - 500.0mg/g - tetracykliny - brojleři kura domácího, prasata ve výkrmu, krůty
eficur 50 mg/ml injekční suspenze
laboratorios hipra s.a. - ceftiofur - injekční suspenze - 50mg/ml - cefalosporiny třetí generace - prasata, skot
enro-k 10 % perorální roztok
laboratorios karizoo, s.a. - enrofloxacin - perorální roztok - 10% - fluorochinolony - krůty, kur domácí